"Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), an innovative global healthcare company, announced that the Board of Directors approved a resolution on February 28, 2025 to establish upper limits for the acquisition of its own shares based on the Articles of Incorporation pursuant to the provisions of Article 165, Paragraph 2 of the Companies Act. The details are as follows.
1. Reason for acquisition of own shares:
Daiichi Sankyo's shareholder return policy under the 5-year business plan (FY2021-FY2025) is to further enhance shareholder value through dividend increase in line with profit growth and flexible acquisition of its own shares.
In order to take flexible actions in response to the current situation where Daiichi Sankyo believes that its future profitability is not fully reflected in its share price, Daiichi Sankyo has established upper limits of 17 million shares and JPY50.0 billion for acquisition of its own shares.
2. Details of acquisition:
(1) Class of shares to be acquired: Ordinary shares of Daiichi Sankyo
(2) Total number of shares to be acquired: 17,000,000 shares (maximum); 0.91% issued shares (excluding own shares)
(3) Aggregate amount of acquisition cost: JPY50.0 billion (maximum)
(4) Acquisition period: From March 3, 2025 to April 24, 2025
(5) Acquisition method: Purchase through market transaction on the Tokyo Stock Exchange.
Depending on market environment and other factors, some or all of the acquisition may not be completed.
Number of own shares held by Daiichi Sankyo as of January 31, 2025: - Total number of issued shares (excluding own shares): 1,877,212,461 shares - Number of own shares: 31,109,668 shares (Note) The number of own shares includes 1,782,000 shares held by the Stock Grant ESOP (Employee Stock Ownership Plan) Trust.
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world.